Cochrane Review: Dipyridamole for Preventing Major Vascular Events in Patients With Vascular Disease
Why the study?
Does dipyridamole reduce vascular death or vascular events in patients with nonembolic arterial vascular disease?
Population
19,842 patients across 26 randomized trials with nonembolic arterial vascular disease
Comparison
Dipyridamole in the presence or absence of other… vs No drug or an antiplatelet drug other than…
Design
Meta-analysis, Randomized trials with concealed treatment allocation
Authors
Discussion
Loading...
Member takes
Implication
Dipyridamole does not significantly reduce vascular death in patients with arterial vascular disease, and its modest benefit on vascular events is driven by a single trial in cerebral ischemia.
Structured PICO
Does dipyridamole reduce vascular death or vascular events in patients with nonembolic arterial vascular disease?
P
Population
19,842 patients across 26 randomized trials with nonembolic arterial vascular disease
I
Intervention
Dipyridamole in the presence or absence of other antiplatelet drugs
C
Comparator
No drug or an antiplatelet drug(s) other than dipyridamole (chiefly aspirin)
O
Outcome
Vascular death and vascular events (death from all vascular causes, nonfatal stroke, or nonfatal myocardial infarction)composite
Dipyridamole does not significantly reduce vascular death in patients with arterial vascular disease, and its modest benefit on vascular events is driven by a single trial in cerebral ischemia.
Limitations
- Benefit in vascular events was found only in a single large trial and only in patients presenting after cerebral ischemia
Cite This Study
Schryver et al. (2003) studied this question.